The role of cytotoxic drugs in the treatment of central nervous system gliomas

Acta Neurologica Belgica

Volumn 110, Issue 1, 2010, Pages 1-14

  Neyns, Bart ^a   D'Haeseleer, Miguel ^b   Rogiers, Anne ^c   Van De Cauter, Joy ^d   Chaskis, Cristo ^e   Michotte, Alex ^b   Strik, Herwig ^f  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c FAGG   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Centre Hospitalier Universitaire de Charleroi   (Belgium)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Chemotherapy; Glioblastoma; MGMT; Nitrosurea; Temozolomide

Indexed keywords

5 (3 METHYLTRIAZEN 1 YL)IMIDAZOLE 4 CARBOXAMIDE; AFLIBERCEPT; ANTIEMETIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CETUXIMAB; CILENGITIDE; CISPLATIN; COTRIMOXAZOLE; CYTOTOXIC AGENT; DACARBAZINE; DASATINIB; DRUG METABOLITE; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VATALANIB; VINCRISTINE; XL 184; CYTOTOXIN;

ADJUVANT THERAPY; ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA METHYLATION; DRUG ACTIVITY; DRUG DOSE INCREASE; GENETIC MARKER; GLIOBLASTOMA; GLIOMA; HUMAN; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROSURGERY; NEUTROPENIA; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE CARE; PROGNOSIS; PROMOTER REGION; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; VOMITING; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; MALE; METHODOLOGY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTOTOXINS; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE;

EID: 77953703731     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001;19:509-18.
2. Baer Jc, Freeman AA, Newlands ES, Watson AJ, Rafferty JA. et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993;67:1299-302.
3. Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95.
4. Beale P, Judson I, Moore S, Statkevich P, Marco A. et al. Effect of gastric pH on the relative oral bio - availability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol. 1999;44:389-94.
5. Belda-Iniesta C, Carpeno JdeC, Saenz EC, Gutierrez M, Perona R. et al. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther. 2006;5:912-4.
6. Blakeley J, Grossman S. Anaplastic oligodendroglioma. Curr Treat Options Neurol. 2008;10:295-307.
7. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ. et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40:484-8.
8. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-66.
9. Brada M, Judson I, Beale P, Moore S, Reidenberg P. et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81:1022-30.
10. Brada M, Viviers L, Abson C, Hines F, Britton J. et al. Phase II study of primary temozolomide chemo - therapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-21.
11. Brandes AA, Ermani M, Basso U, Amista P, Berti F. et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol. 2001;12:255-7.
12. Brandes AA, Tosoni A, Amista P, Nicolardi L, Grosso D. et al. How effective is BCNU in recurrent glio - blastoma in the modern era? A phase II trial. Neurology. 2004;63:1281-4.
13. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V. et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neurooncologia (GICNO). Br J Cancer. 2006;95:1155-60.
14. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H. et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-7.
15. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13:2038-45.
16. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM. et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
17. Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008;26:1012-3; author reply 1013.
18. Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009a; 115:1734-43.
19. Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009b; 91:359-67.
20. Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol. 2009c.
21. Chamberlain MC, Raizer J. Antiangiogenic therapy for high-grade gliomas. CNS Neurol Disord Drug Targets. 2009d; 8:184-94.
22. Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J. et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004;100:605-11.
23. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D. et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357-61.
24. Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol. 2001;28:13-8.
25. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB. et al. Randomized phase II trial of chemoradio - therapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27:3861-7.
26. Combs SE, Schulz-Ertner D, Hartmann C, Welzel T, Timke C. et al. Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)-Eudract number 2005-003911-63; NCT00311857. J Clin Oncol (Meeting Abstracts). 2008;26:2077-.
27. De Groot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF. et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomideresistant glioblastoma: NABTC 0601. J Clin Oncol (Meeting Abstracts). 2008;26:2020.
28. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-23.
29. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH. et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007;83:53-60.
30. Djedid R, Kiss R, Lefranc F. Targeted therapy of glioblastomas: a 5-year view. Therapy. 2009;6:351-370.
31. Everaert E, Neyns B, Joosens E, Strauven T, Branle F. et al. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol. 2004;70:37-48.
32. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A. et al. Gefitinib in patients with progressive highgrade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047-51.
33. Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A. et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer. 2004;91:1038-44.
34. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40.
35. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neuroon col. 1996;27:149-55.
36. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294-304. (Pubitemid 46206983)
37. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
38. Hegi ME, Liu L, Herman JG, Stupp R, Wick W. et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-99.
39. Hegi ME, Murat A, Lambiv WL, Stupp R. Brain tumors: molecular biology and targeted therapies. Ann Oncol. 2006;17 Suppl 10: x191-7.
40. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H. et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133-8.
41. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66:3987-91.
42. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R. et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11:341-7.
43. Idbaih A, Ducray F, Sierra Del Rio M, Hoang-Xuan K, Delattre JY. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist. 2008;13:978-92.
44. Janinis J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G. et al. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol. 2000;17:106-10.
45. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM. et al. A t (1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-61.
46. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P. et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 2003;97:1963-8.
47. Kreisl TN, Kim L, Moore K, Duic P, Royce C. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-5.
48. Lee SM, Brada M, Gabe R, Stenning S, Thompson L. et al. 2008, A randomised trial of temozolomide vs PCV chemotherapy for recurrent malignant glioma (MRC BR12).
49. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist. 2007;12:1395-403.
50. Levin VA. The place of hydroxyurea in the treatment of primary brain tumors: Semin Oncol. 1992;19:34-9.
51. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC. et al. The 2007 WHO classification of tumours of the central nervous systemx. Acta Neuropathol. 2007;114:97-109.
52. Michotte A, Neyns B, Chaskis C, Sadones J, Veld P. Neuropathological and molecular aspects of lowgrade and high-grade gliomas. Acta Neurol Belg. 2004;104:148-53.
53. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-66.
54. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N. et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009;92:57-63.
55. Nagane M, Nozue K, Shimizu S, Waha A, Miyazaki H. et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma-analysis of O (6)-methylguanine-DNA methyltransferase status. J Neurooncol. 2008.
56. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB. et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-91.
57. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H. et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996;32 A: 2236-41.
58. Neyns B, Chaskis C, Joosens E, Menten J, D'hondt L. et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest. 2008;26:269-77.
59. Neyns B, Sadones J, Chaskis C, DeRidder M, Keyaerts M. et al. The role of chemotherapy in the treatment of low-grade glioma. A review of the literature. Acta Neurol Belg. 2005;105:137-43.
60. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L. et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol, 2009.
61. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M. et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009;92:149-55.
62. Osoba D, Brada M, Yung, WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18:1481-91.
63. Pace A, Vidiri A, Galie E, Carosi M, Telera S. et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722-6.
64. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ. et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-12.
65. Prados MD, Chang SM, Butowski N, Deboer R, Parvataneni R. et al. Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. J Clin Oncol. 2009;27:579-584.
66. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH. et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646-51.
67. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B. et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008;26:4659-65.
68. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R. et al. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer, 2008.
69. Sanson M, Marie, Y, Paris S, Idbaih A, Laffaire J. et al. Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. J Clin Oncol. 2009;27:4150-4154.
70. Sant M, VanDer Sanden G, Capocaccia R. Survival rates for primary malignant brain tumours in Europe. EUROCARE Working Group. Eur J Cancer. 1998;34:2241-7.
71. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H. et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900-8.
72. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG. et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359-67.
73. Smith JS, Perry A, Borell TJ, Lee HK, O'fallon J. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-45.
74. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-8.
75. Strik HM, Buhk JH, Bock C, Hoffmann AL, Wrede A. et al. Tegwondo: Development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent brain tumors. J Clin Oncol (Meeting Abstracts), 2008a; 26:13016.
76. Strik HM, Buhk JH, Wrede A, Hoffmann AL, Bock HC. et al. Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Molecular Medicine Reports. 2008b; 1:863-867.
77. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I. et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-82.
78. Stupp R, Goldbrunner R, Neyns B, Schlegel U, Clement P. et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts). 2007;25:2000.
79. Stupp R, Hegi ME, Mason WP, VanDen Bent MJ, Taphoorn MJ. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-66.
80. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
81. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R. et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937-44.
82. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA. et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-11.
83. Trent S, Kong A, Short Sc, Traish D, Ashley S. et al. Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol. 2002;57:247-51.
84. Van Den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM. et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27:1268-74.
85. Van Den Bent MJ, Kros JM, Heimans JJ, Pronk LC, Van Groeningen CJ. et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology, 1998;51:1140-5.
86. Vogelbaum MA, Berkey B, Peereboom D, MacDonald D, Giannini C. et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167-75.
87. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA. et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-9.
88. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11:80-91.
89. Wedge SR, Newlands ES. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer. 1996;73:1049-52.
90. Wen PY, Kesari S. Malignant Gliomas in Adults. N Engl J Med. 2008;359:492-507.
91. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M. et al. Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. J Clin Oncol. 2007;25:3357-3361.
92. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol. 2005;23:4235-6; author reply 4236.
93. Wick W, Weller M, O. Neurooncology Working Group of the German Cancer S. Randomized phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04. J Clin Oncol (Meeting Abstracts). 2008;26: LBA2007.
94. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA. et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73.
95. Yung WK, Albright RE, Olson J, Fredericks R, Fink K. et al. A phase II study of temozolomide vs. pro - carbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-93.
96. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T. et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91:329-36.